【摘要】 目的　检测冠心病 (CHD)、糖尿病 (DM)、系统性红斑狼疮 (SLE)患者血浆中的可溶性血管内皮细胞蛋白C受体 (sEPCR)水平 ,以探讨sEPCR在不同疾病患者血浆中表达水平及其临床意义。方法　采用酶联免疫双抗体夹心法检测 34例CHD、42例DM、6 3例SLE患者及 2 0名正常人 (NC)血浆中的sEPCR水平。结果　sEPCR在DM患者血浆中的表达水平明显高于正常对照血浆 (P <0 .0 5 ) ;SLE合并血栓及SLE无血栓患者的sEPCR水平均高于NC组 (P <0 .0 0 5及P <0 .0 0 1) ,但SLE两组之间的sEPCR水平差异无显著性 (P >0 .0 5 ) ;冠心病患者血浆中sEPCR水平与正常对照组差异无显著性(P >0 .0 5 )。结论　sEPCR在DM病、SLE中升高可能与血管内皮损伤、炎性反应过程有关更多还原

【Abstract】 Objective To evaluate the clinical significance of plasma soluble endothelial protein C receptor(sEPCR) level in patients with coronary heart disease (CHD), diabetes mellitus (DM) and systemic lupus erythematosus (SLE) . Methods ELISA of antibody sandwiched principle was used to detect sEPCR in 34 patients with CHD, 42 with DM Ⅱ, 63 with SLE and 20 normal controls (NC). Results The plasma level of sEPCR in patients with DM was higher than that in NC group (P<0.05). The sEPCR level in SLE patients with thrombosis and non thrombosis are higher than that in NC group (P<0.005 and P<0.001,respectively). There is no significant difference between the two groups of SLE (P>0.05), and between the CHD and NC groups. Conclusion sEPCR level increased in DM and SLE, it seems related to the process of inflammatory reaction and damage of endothelial cell.更多还原